Australia's Nyrada rises on nod to start brain injury drug's clinical trial
07/02/2025 03:42
** Nyrada NYR.AX soars 9.2% to A$0.083, highest since Jan.
23; set for biggest intraday pct gain since Dec. 16, 2024
** Biotechnology co gets Human Research Ethics Committee's
(HREC) approval to start its first-in-human Phase Ia clinical
trial for its lead drug candidate NYR-BI03
** NYR-BI03 is used to treat stroke, traumatic brain injury
** Stock down 8.5% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))